Skip to main content
. Author manuscript; available in PMC: 2019 Mar 19.
Published in final edited form as: Oncology (Williston Park). 2018 May 15;32(5):216–222.

Table 2.

Monitoring Parameters for CDK4/6 Inhibitors

Drug Dose and
Schedule
Pregnancy
Testa
CBC and
Differential
Liver Tests
(AST, ALT,
and Total
Bilirubin)
Serum
Electrolytes
(K, Ca, Mg,
Phos)
ECG
Palbociclib 125 mg daily, 3 wk on, 1 wk off Baseline Baseline, every 2 wk for 2 mo, monthly for first 6 mo, then every 3 mod NA NA NA
Ribociclib 600 mg daily, 3 wk on, 1 wk off Baseline Baseline, every 2 wk for 2 mo, monthly for 4 mo Baseline, every 2 wk for 2 mo, monthly for 4 mo Baseline, monthly for 6 mo Baseline, day 14 of cycle 1, day 1 of cycle 2
Abemaciclib 150 mg twice dailyb OR 200 mg twice dailyc Baseline Baseline, every 2 wk for 2 mo, monthly for 2 mo Baseline, every 2 wk for 2 mo, monthly for 2 mo NA NA
a

[In women of childbearing potential. Authors: please provide explanatory footnote (see “Pregnancy Test” column header).]

b

When given with fulvestrant.

c

When given alone.

d

If no more than grade 1 or 2 neutropenia in the first 6 months

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; ECG = electrocardiogram; NA = not applicable